


Survey: Impact of COVID-19 Pandemic on Rare Disease Patients in Canada

	Question	
1.	<p>At this time, to the best of your knowledge, what is the most likely impact of COVID-19 on (adequate) supply of your company’s drugs to Canadian patients? If the answer varies by drug, please provide either specific drug information or respond in general across all drugs.</p>	<p>We continue to monitor the worldwide impact of COVID-19 very closely, and have deployed business continuity plans to ensure the continued safety, quality and supply of our medicines. While this remains a very dynamic situation, we do not foresee supply interruptions related to COVID-19 in Canada at this time. We continue to work closely with our third-party logistics providers and have a plan in place to support the uninterrupted supply of medicines for Canadians.</p>
2.	<p>If interruption or shortage in drug supply were anticipated or took place, where could Canadian patients find information about the situation and any plans for addressing or mitigating the impact? Is there a website, information line, or contact person?</p>	<p>Any anticipated drug shortage in Canada will be listed on the Health Canada Drug Shortage Website.</p> <p>Any future shortage can be reported by a pharmacy or through our AstraZeneca Canada website astrazeneca.ca.</p>
3.	<p>This question addresses any clinical trials that your company has at this time that includes Canadian sites or Canadian patients in other countries. At this time, to the best of your knowledge, have you experienced or do you anticipate any interruptions, delays, or modifications in the conduct of these trials due to COVID-19? Please describe any modifications or other adjustments.</p>	<p>Ensuring that patients who are enrolled in ongoing clinical trials are able to continue their treatment is a central priority and we are making every effort to ensure that these patients continue to receive appropriate care and monitoring. To facilitate continuity of supply and care for participants, AstraZeneca is adhering to Health Canada’s guidance on the management of clinical trials during the COVID-19 pandemic: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/management-clinical-trials-during-covid-19-pandemic.html</p>
4.	<p>To the best of your knowledge, are there any clinical trials that will not take place or will be delayed as a result of COVID-19? Please describe.</p>	<p>Our clinical research is crucial to the development of innovative new medicines, and we are taking appropriate measures to ensure continuity and</p>

		mitigate any impact to our research and development programs.
5.	Where can patients find information about any increased risk of getting COVID-19 or increased impact of COVID-19 due to any medications provided by your company?	Please check our AstraZeneca Canada website astrazeneca.ca .
6.	To the best of your knowledge, are there any changes in patient support programs that are anticipated or planned, related to issues due to COVID-19? Please describe.	AstraZeneca has taken important steps with all of our clinics to ensure the safe and continuous supply of our medicines to Canadian patients. This includes deploying business continuity plans to facilitate the ongoing care and support of patients accessing treatment through our Oncology Patient Support Program or CONNECT360 Patient Support Program, and taking appropriate steps to safeguard the health of patients and medical staff at all program clinics and pharmacies.
7.	How can patients or patient organizations find updated information about your company's policies, plans, or actions related to COVID-19? How will you communicate with patients or patient groups?	Please check our AstraZeneca Canada website astrazeneca.ca .
8.	Is there any other information that you wish to communicate share at this time?	